| Summary: | An impaired coagulation process has been described in patients with severe or critical coronavirus disease (COVID-19). Nevertheless, the implication of coagulation-related genes has not been explored. We aimed to evaluate the impact of <i>F5</i> rs6025 and <i>SERPINE1</i> rs6092 on invasive mechanical ventilation (IMV) requirement and the levels of coagulation proteins among patients with severe COVID-19. Four-hundred fifty-five patients with severe COVID-19 were genotyped using TaqMan assays. Coagulation-related proteins (P-Selectin, D-dimer, P-selectin glycoprotein ligand-1, tissue plasminogen activator [tPA], plasminogen activator inhibitor-1, and Factor IX) were assessed by cytometric bead arrays in one- and two-time determinations. Accordingly, <i>SERPINE1</i> rs6092, P-Selectin (GG 385 pg/mL vs. AG+AA 632 pg/mL, <i>p</i> = 0.0037), and tPA (GG 1858 pg/mL vs. AG+AA 2546 pg/mL, <i>p</i> = 0.0284) levels were different. Patients carrying the CT <i>F5</i>-rs6025 genotype exhibited lower levels of factor IX (CC 17,136 pg/mL vs. CT 10,247 pg/mL, <i>p</i> = 0.0355). Coagulation proteins were also different among IMV patients than non-IMV. PSGL-1 levels were significantly increased in the late stage of COVID-19 (>10 days). The frequencies of <i>F5</i> rs6025 and <i>SERPINE1</i> rs6092 variants were not different among IMV and non-IMV. The <i>SERPINE1</i> rs6092 variant is related to the impaired coagulation process in patients with COVID-19 severe.
|
|---|